BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15176002)

  • 21. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.
    Stacchiotti S; Pedeutour F; Negri T; Conca E; Marrari A; Palassini E; Collini P; Keslair F; Morosi C; Gronchi A; Pilotti S; Casali PG
    Int J Cancer; 2011 Oct; 129(7):1761-72. PubMed ID: 21128251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease.
    McArthur GA
    J Natl Compr Canc Netw; 2007 May; 5(5):557-62. PubMed ID: 17509258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor.
    Sawyers CL
    J Clin Oncol; 2002 Sep; 20(17):3568-9. PubMed ID: 12202652
    [No Abstract]   [Full Text] [Related]  

  • 24. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients.
    Kérob D; Porcher R; Vérola O; Dalle S; Maubec E; Aubin F; D'Incan M; Bodokh I; Boulinguez S; Madelaine-Chambrin I; Mathieu-Boue A; Servant JM; de Kerviler E; Janin A; Calvo F; Pedeutour F; Lebbe C
    Clin Cancer Res; 2010 Jun; 16(12):3288-95. PubMed ID: 20439456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib.
    Wicherts DA; van Coevorden F; Klomp HM; van Huizum MA; Kerst JM; Haas RL; van Boven HH; van der Hage JA
    World J Surg Oncol; 2013 Mar; 11():59. PubMed ID: 23496933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.
    Han A; Chen EH; Niedt G; Sherman W; Ratner D
    Arch Dermatol; 2009 Jul; 145(7):792-6. PubMed ID: 19620561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
    Rutkowski P; Van Glabbeke M; Rankin CJ; Ruka W; Rubin BP; Debiec-Rychter M; Lazar A; Gelderblom H; Sciot R; Lopez-Terrada D; Hohenberger P; van Oosterom AT; Schuetze SM; ;
    J Clin Oncol; 2010 Apr; 28(10):1772-9. PubMed ID: 20194851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.
    Kasper B; Lossignol D; Gil T; Flamen P; De Saint Aubain N; Awada A
    Anticancer Drugs; 2006 Nov; 17(10):1223-5. PubMed ID: 17075323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate].
    Zhu JH; Li QW; Xiao WH; Sun JZ; Wang RL; Lu JY
    Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):470-2. PubMed ID: 21875491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencing.
    Hong JY; Liu X; Mao M; Li M; Choi DI; Kang SW; Lee J; La Choi Y
    PLoS One; 2013; 8(7):e69752. PubMed ID: 23922791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
    Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T
    Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate.
    Thomison J; McCarter M; McClain D; Golitz LE; Goldenberg G
    J Cutan Pathol; 2008 Nov; 35(11):1003-6. PubMed ID: 18544062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Good response to treatment with the selective tyrosine-kinase inhibitor imatinib in a patient with metastatic dermatofibrosarcoma protuberans].
    Baars A; Pinedo HM
    Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2072-6. PubMed ID: 14606355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior.
    McArthur GA
    Curr Opin Oncol; 2006 Jul; 18(4):341-6. PubMed ID: 16721128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.
    Koseła-Paterczyk H; Rutkowski P
    Expert Rev Anticancer Ther; 2017 Dec; 17(12):1107-1116. PubMed ID: 28988501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer.
    Handolias D; McArthur GA
    Future Oncol; 2008 Apr; 4(2):211-7. PubMed ID: 18407734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New molecular approaches in dermatofibrosarcoma protuberans].
    Kaya G
    Rev Med Suisse; 2009 Jul; 5(211):1519-24. PubMed ID: 19694363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Targeted therapy of dermatofibrosarcoma with imatinib].
    Ugurel S
    J Dtsch Dermatol Ges; 2007 Mar; 5(3):261. PubMed ID: 17338806
    [No Abstract]   [Full Text] [Related]  

  • 39. Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement.
    Greco A; Roccato E; Miranda C; Cleris L; Formelli F; Pierotti MA
    Int J Cancer; 2001 May; 92(3):354-60. PubMed ID: 11291071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dermatofibrosarcoma protuberans: a partial response to imatinib therapy.
    Mehrany K; Swanson NA; Heinrich MC; Weenig RH; Lee KK; White CR; Devere TS
    Dermatol Surg; 2006 Mar; 32(3):456-9. PubMed ID: 16640697
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.